| PubChem CID | Drug (INN) | Original Targets (Gene Symbol) | Original Indications |
|---|---|---|---|
| 5566 | trifluoperazine | ADCY1, ADCY3, ADCY4, ADCY6, ADCY8, ADCY9, ADRA1A, ANXA10, ANXA13, ANXA2, ANXA3, ANXA5, ANXA6, CALM1, CALY, DRD2, DRD4, DRD5, F2, FDPS, GRK7, LTB4R, MYH1, MYH2, MYH4, MYH7B, MYL1, MYL12A, MYL2, MYL7, MYL9, MYLK, MYO15A, MYO18B, MYO1C, MYO1D, MYO1E, MYO3A, MYO3B, MYO5B, MYO5C, NDUFAF3, NDUFS5, S100A4, SLC1A5, SLC5A11, SLC7A5, TNNC1, TNNI3, TNNT2 | Antipsychotic Agents, Antiemetics, Alcoholic Intoxication, Chronic, Bipolar Disorder, Catatonia, Hallucinations, Psychotic Disorders, Schizophrenia, Paranoid Schizophrenia, Brain Injuries, Mental deficiency, Alcoholism, Alcohol abuse, Bipolar disorder, Bipolar I disorder, Hallucination, Psychotic disorder, Schizophrenia, paranoid type, Brain injury |
| Drug Name (INN) |
Predicted Drug Target (Uniprot AC) |
Target Prediction Score (Range: 0~1) |
Binding or Not (Positive binding: 1) |
Novel Positives (Novel candidate: 1) |
|---|---|---|---|---|
| trifluoperazine | P04058 | 0.0439 | 0 | - |
| trifluoperazine | TFF1 (P04155) | 0.0433 | 0 | - |
| trifluoperazine | Q9N587 | 0.0433 | 0 | - |
| trifluoperazine | O35435 | 0.0429 | 0 | - |
| trifluoperazine | P22906 | 0.0422 | 0 | - |
| trifluoperazine | IGFBP3 (P17936) | 0.0421 | 0 | - |
| trifluoperazine | Q9X286 | 0.0421 | 0 | - |
| trifluoperazine | RIOK1 (Q9BRS2) | 0.0415 | 0 | - |
| trifluoperazine | GABRA6 (Q16445) | 0.0413 | 0 | - |
| trifluoperazine | LIG1 (P18858) | 0.0412 | 0 | - |
| trifluoperazine | CACNG2 (Q9Y698) | 0.041 | 0 | - |
| trifluoperazine | ROCK1 (Q13464) | 0.041 | 0 | - |
| trifluoperazine | ATOX1 (O00244) | 0.0405 | 0 | - |
| trifluoperazine | IL25 (Q9H293) | 0.0399 | 0 | - |
| trifluoperazine | LGALS13 (Q9UHV8) | 0.0398 | 0 | - |
| trifluoperazine | AURKC (Q9UQB9) | 0.0397 | 0 | - |
| trifluoperazine | PSG5 (Q15238) | 0.0389 | 0 | - |
| trifluoperazine | P05045 | 0.0387 | 0 | - |
| trifluoperazine | PRSS1 (P07477) | 0.0386 | 0 | - |
| trifluoperazine | LTA4H (P09960) | 0.0384 | 0 | - |
| trifluoperazine | NDUFB3 (O43676) | 0.0383 | 0 | - |
| trifluoperazine | CHRM4 (P08173) | 0.0378 | 0 | - |
| trifluoperazine | DAPK3 (O43293) | 0.0375 | 0 | - |
| trifluoperazine | STK24 (Q9Y6E0) | 0.0361 | 0 | - |
| trifluoperazine | ANXA4 (P09525) | 0.0358 | 0 | - |
| trifluoperazine | NTRK3 (Q16288) | 0.0357 | 0 | - |
| trifluoperazine | INSR (P06213) | 0.0355 | 0 | - |
| trifluoperazine | ACVR2B (Q13705) | 0.0352 | 0 | - |
| trifluoperazine | ACPP (P15309) | 0.0349 | 0 | - |
| trifluoperazine | ADCYAP1R1 (P41586) | 0.0347 | 0 | - |
| trifluoperazine | SSTR2 (P30874) | 0.0345 | 0 | - |
| trifluoperazine | PROK1 (P58294) | 0.0344 | 0 | - |
| trifluoperazine | HMGCR (P04035) | 0.0343 | 0 | - |
| trifluoperazine | EPHB2 (P29323) | 0.0342 | 0 | - |
| trifluoperazine | NDUFA2 (O43678) | 0.0334 | 0 | - |
| trifluoperazine | CCNI (Q14094) | 0.0333 | 0 | - |
| trifluoperazine | DGAT1 (O75907) | 0.0329 | 0 | - |
| trifluoperazine | SBK3 (P0C264) | 0.0324 | 0 | - |
| trifluoperazine | DAPK1 (P53355) | 0.0314 | 0 | - |
| trifluoperazine | PCNA (P12004) | 0.0303 | 0 | - |
| trifluoperazine | TXK (P42681) | 0.0301 | 0 | - |
| trifluoperazine | PTK2 (Q05397) | 0.0295 | 0 | - |
| trifluoperazine | P0A7R5 | 0.029 | 0 | - |
| trifluoperazine | SRMS (Q9H3Y6) | 0.028 | 0 | - |
| trifluoperazine | MAP2K1 (Q02750) | 0.0279 | 0 | - |
| trifluoperazine | SRPK3 (Q9UPE1) | 0.0272 | 0 | - |
| trifluoperazine | PSMB4 (P28070) | 0.027 | 0 | - |
| trifluoperazine | IFNK (Q9P0W0) | 0.0264 | 0 | - |
| trifluoperazine | CYB5A (P00167) | 0.0263 | 0 | - |
| trifluoperazine | SIK3 (Q9Y2K2) | 0.0262 | 0 | - |
| Drug (INN) |
Drug Mechanism (Gene ontology) |
Mechanism Score (Range: 0~1) |
Positive or not (Positive: 1) |
|---|---|---|---|
| trifluoperazine | GO:0006281 DNA repair | 1 | 1 |
| trifluoperazine | GO:0031570 DNA integrity checkpoint | 1 | 1 |
| trifluoperazine | GO:0007049 cell cycle | 0.875 | 1 |
| trifluoperazine | GO:0008283 cell population proliferation (viability) | 0.7 | 1 |
| trifluoperazine | GO:0071456 cellular response to hypoxia | 0.3333 | 0 |
| trifluoperazine | GO:0001525 angiogenesis | 0.2857 | 0 |
| trifluoperazine | GO:0008283 cell population proliferation | 0.25 | 0 |
| trifluoperazine | GO:0006954 inflammatory response | 0.2 | 0 |
| trifluoperazine | GO:0008219 cell death | 0.0625 | 0 |
| trifluoperazine | GO:0006096 glycolytic process | 0 | 0 |
| trifluoperazine | GO:0016477 cell migration | 0 | 0 |
| trifluoperazine | GO:0001837 epithelial to mesenchymal transition | 0 | 0 |
| trifluoperazine | GO:0002418 immune response to tumor cell | 0 | 0 |
| trifluoperazine | GO:0010833 telomere maintenance via telomere lengthening | 0 | 0 |
| trifluoperazine | GO:0001570 vasculogenesis | 0 | 0 |
| trifluoperazine | GO:0007155 cell adhesion | 0 | 0 |
| trifluoperazine | GO:0016049 cell growth | 0 | 0 |
| trifluoperazine | GO:0006915 apoptotic process | 0 | 0 |
| Drug (INN) |
Cancer Type | Indication Score (Range: 0~1) |
Cancer Drug or Not (Positive indication: 1) |
Novel Positives (Novel candidate: 1) |
|---|---|---|---|---|
| trifluoperazine | Cancer(general) | 0.6236 | 0 | - |